Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5288745 | 0.84 | CASP2 (0.47) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL13431642 | 0.84 | CASP2 (0.47) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL10631439 | 0.80 | CASP2 (0.60) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL10605642 | 0.79 | CASP2 (0.54) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL14952562 | 0.78 | CASP2 (0.59) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL11234059 | 0.77 | CASP2 (0.58) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL17205672 | 0.77 | CASP2 (0.53) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL11234062 | 0.77 | CASP2 (0.58) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL14891069 | 0.77 | CASP2 (0.52) | CASP2EPHX1MEN1KMT2AFAAH | |
| SCHEMBL16804265 | 0.77 | TSHR (0.36) | CASP2EPHX1MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147854-B2 | Cosmetics comprising a modified organopolysiloxane | DOW CORNING TORAY COMPANY, LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8013094-B2 | Gelling agents and gelatinous compositions | DOW CORNING TORAY COMPANY, LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100029862-A1 | Gelling Agents And Gelatinous Compositions | DOW CORNING TORAY COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100028391-A1 | Cosmetics Comprising A Modified Organopolysiloxane | DOW CORNING TORAY COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028391-A1 | Cosmetics Comprising A Modified Organopolysiloxane | H1-0, H1-2, CHRM1 | CASP2 4144/4885EPHX1 1332/4885MEN1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.